Ariceum Therapeutics’ proprietary radiopharmaceutical cancer therapy, 225Ac-SSO110 receives US FDA orphan drug designation: Berlin, Germany Friday, February 7, 2025, 11:00 Hrs [ ...

Tarlatamab is under review as a treatment for adult patients with advanced SCLC who have disease ... including neuroendocrine prostate cancer (in phase 1) and potentially glioblastoma multiforme ...

The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD. J&J’s $2 billion play for ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a $2 billion market cap company specializing in pharmaceutical preparations, announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial ...

But the terms mean the same thing. There are 2 key groups of neuroendocrine cancer: neuroendocrine tumours (NETs) neuroendocrine carcinomas (NECs) Neuroendocrine cancer can start in any part of the ...

SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more ...

For information and support, you can call the Cancer Research UK information nurses on freephone 0808 800 4040. The lines are open from 9am to 5pm, Monday to Friday. Most people have several tests to ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Feb. 4, 2025 — A research team has identified a critical event driving tumor growth in a type of medulloblastoma -- and a way to block ... Routine Brain MRI Screening in Asymptomatic Late Stage ...